Premium
Limited antigenic variation in the T rypanosoma cruzi candidate vaccine antigen TSA ‐1
Author(s) -
Knight J. M.,
Zingales B.,
Bottazzi M. E.,
Hotez P.,
Zhan B.
Publication year - 2014
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/pim.12130
Subject(s) - biology , trypanosoma cruzi , antigenic variation , antigen , epitope , virology , chagas disease , immunology , genetics , parasite hosting , world wide web , computer science
Summary Chagas disease (American trypanosomiasis caused by T rypanosoma cruzi ) is one of the most important neglected tropical diseases in the W estern H emisphere. The toxicities and limited efficacies of current antitrypanosomal drugs have prompted a search for alternative technologies such as a therapeutic vaccine comprised of T . cruzi antigens, including a recombinant antigen encoding the N ‐terminal 65 kDa portion of Trypomastigote surface antigen‐1 ( TSA ‐1). With at least six known genetically distinct T . cruzi lineages, variability between the different lineages poses a unique challenge for the development of broadly effective therapeutic vaccine. The variability across the major lineages in the current vaccine candidate antigen TSA ‐1 has not previously been addressed. To assess the variation in TSA ‐1, we cloned and sequenced TSA ‐1 from several different T . cruzi strains representing three of the most clinically relevant lineages. Analysis of the different alleles showed limited variation in TSA ‐1 across the different strains and fit with the current theory for the evolution of the different lineages. Additionally, minimal variation in known antigenic epitopes for the HLA ‐A 02 allele suggests that interlineage variation in TSA ‐1 would not impair the range and efficacy of a vaccine containing TSA ‐1.